Theolytics, a biotechnology company, announced on Thursday that it has named Michael Grey as the executive chair of the company's board of directors.

Grey is to succeed Dr Ken Powell, who is retiring from the board having served as chair since 2019.

Grey is the founder of a number of biotechnology companies. Presently, he is the chair/executive chair of Mirum Pharmaceuticals, Inc., Sorriso Pharmaceuticals, Inc., Reneo Pharmaceuticals, Inc., Spruce Biosciences, Inc. and Plexium Inc. He also works as Venture Partner at Pappas Capital.

He has more than 45 years of experience in the pharmaceutical and biotechnology industries, and has served in senior positions such as president and chief executive officer of Amplyx Pharmaceuticals; Lumena Pharmaceuticals; president and chief executive officer of SGX Pharmaceuticals, Inc; president and chief executive officer of Trega Biosciences, Inc., and president of BioChem Therapeutic Inc. He started his career with Glaxo, Inc. and Glaxo Holdings plc, where he worked in various roles resulting in his position as vice president, Corporate Development and head of International Licensing.